Notes
incremental cost-effectiveness ratios
Reference
Hoyle M, et al. Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer. Value in Health 16: 288-96, No. 2, Mar 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2012.11.001
Rights and permissions
About this article
Cite this article
Cetuximab, irinotecan, panitumumab too costly in mCRC. PharmacoEcon Outcomes News 676, 6 (2013). https://doi.org/10.1007/s40274-013-0317-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0317-6